Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Hwang, Kyung Sun ^a   Cho, Won Kyung ^a   Yoo, Jinsang ^a   Yun, Hwan Jung ^b   Kim, Samyong ^b   Im, Dong Soo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; FLUCYTOSINE; GAMMA INTERFERON; INTERLEUKIN 12; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; FLUOROURACIL; GREEN FLUORESCENT PROTEIN; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL LINE; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; HELA CELL; KIDNEY TUMOR; METABOLISM; METHODOLOGY; NEOPLASM; SPLEEN; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSINE DEAMINASE; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLUOROURACIL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PRODRUGS; SPLEEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 26844574675     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-51     Document Type: Article

References (57)

1. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SL: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995, 92:2577-2581
2. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, Woo SL: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996, 56:3758-3762
3. Felzmann T, Ramsey WJ, Blaese RM: Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997, 4:1322-1329
4. Cao X, Ju DW, Tao Q, Wang J, Wan T, Wang BM, Zhang W, Hamada H: Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Ther 1998, 5:1130-1136
5. Ju DW, Wang BM, Cao X: Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J Cancer Res Clin Oncol 1998, 124:683-689
6. Drozdzik M, Qian C, Xie X, Peng D, Bilbao R, Mazzolini G, Prieto J: Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol 2000, 32:279-286
7. Toda M, Martuza RL, Rabkin SD: Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 2001, 8:332-339
8. Nakamori M, Iwahashi M, Ueda K, Tsunoda T, Terasawa H, Hamada H, Yamaue H: Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration. Jpn J Cancer Res 2002, 93:706-715
9. Goto T, Nishi T, Kobayashi O, Tamura T, Dev SB, Takeshima H, Kochi M, Kuratsu J, Sakata T, Ushio Y: Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol Ther 2004, 10:929-37.
10. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845
11. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991, 146:3074-3081
12. Wolf SF, Sieburth D, Sypek J: Interleukin 12: A key modulator of immune function. Stem Cells 1994, 12:154-168
13. Brunda MJ: Role of IL12 as an anti-tumour agent: current status and future directions. Res Immunol 1995, 146:622-628
14. Ma X, Trinchieri G: Regulation of interleukin-12 production in antigenpresenting cells. Adv Immunol 2001, 79:55-92
15. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3:409-417
16. Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J: Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999, 5:9-16
17. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548
18. Golab J, Zagozdzon R: Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med 1999, 3:537-544
19. van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, Merkx MA, Adema GJ, de Mulder PH: Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004, 10:2626-2635
20. Burke F: Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol Ther 1999, 5:51-61
21. Shurin MR, Esche C, Peron JM, Lotze MT: Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997, 68:153-174
22. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001, 33:52-61
23. Chada S, Ramesh R, Mhashilkar AM: Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003, 5:463-474
24. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004, 22:1389-1397
25. Beltinger C, Uckert W, Debatin KM: Suicide gene therapy for pediatric tumors. J Mol Med 2001, 78:598-612
26. Yazawa K, Fisher WE, Brunicardi FC: Current progress in suicide gene therapy for cancer. World J Surg 2002, 26:783-789
27. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986, 46:5276-5281
28. Austin EA, Huber BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993, 43:380-387
29. Kilstrup M, Meng LM, Neuhard J, Nygaard P: Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli. J Bacteriol 1989, 171:2124-2127
30. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992, 89:33-37
31. Schilsky RL: Biochemical and clinical pharmacology of 5-fluorouracil. Oncology 1998, 12:13-18
32. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993, 53:5274-5283
33. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transfectd with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994, 91:8302-8306
34. Wygoda MR, Wilson MR, Davis MA, Trosko JE, Rehemtulla A, Lawrence TS: Protection of herpes simplex virus thymidine kinase-transfectd cells from ganciclovir-mediated cytotoxicity by bystander cells: the Good Samaritan effect. Cancer Res 1997, 57:1699-1703
35. Kievit E, Nyati MK, Ng E, Stegman LD, Parsels J, Ross BD, Rehemtulla A, Lawrence TS: Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000, 60:6649-6655.
36. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J, Harvey BG: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997, 8:985-1001
37. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR: Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999, 17:2180-2189
38. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M: Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003, 10:737-744
39. Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Perez-Higueras A, Cortes ML, Paz JF, Isla A, Blazquez MG: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996, 3:491-495
40. Stockhammer G, Brotchi J, Leblanc R, Bernstein M, Schackert G, Weber F, Ostertag C, Mulder NH, Mellstedt H, Seiler R, Yonekawa Y, Twerdy K, Kostron H, De Witte O, Lambermont M, Velu T, Laneuville P, Villemure JG, Rutka JT, Warnke P, Laseur M, Mooij JJ, Boethius J, Mariani L, Gianella-Borradori A: Gene therapy for glioblastoma multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. J Mol Med 1997, 75:300-304
41. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997, 3:1354-1361
42. Klatzmann D, Cherin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, Boccaccio C, Salzmann JL, Herson S: A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998, 9:2585-2594
43. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999, 10:2325-2335
44. Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, McComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. Neurosurg 2000, 92:249-254
45. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M, Yla-Herttuala S: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000, 11:2197-2205
46. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Human Gene Ther 2000, 11:2389-2401
47. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003, 7:851-858
48. Park J-H, Chang S-H, Lee K-M, Lee H-K: Murine sarcoma cells transfected with interleukin-12 are rejected in vivo inducing protective and curative immune response against the parental cells. Mol Cells 1995, 5:595-564
49. Seong YR, Choi S, Lim JS, Lee CH, Lee CK, Im DS: Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. Vaccine 2001, 19:2955-2964
50. Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S, Im DS: Adenovirusmediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the inductio of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther 2004, 11:397-407
51. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang K-S, Yoo J, Choi S, Jung CR, Im DS: Oncolytic effect of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004, 10:938-949
52. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL: Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996, 7:333-342
53. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997, 159:351-359
54. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994, 54:6228-6234
55. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995, 154:5302-5312
56. Pavlovic J, Nawrath M, Tu R, Heinicke T, Moelling K: Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Ther 1996, 3:635-643
57. Freeman SM, Ramesh R, Marrogi AJ: Immune system in suicide-gene therapy. Lancet 1997, 349:2-3